Ofloxacin 50MG, Metronidazole 120 MG with Simethicone 10 MG Suspension is a multi-component oral liquid formulation combining two active pharmaceutical ingredients with simethicone in a specially developed suspension vehicle. The formulation requires careful control of particle dispersion, liquid-phase compatibility, viscosity, flavour, and physical stability. For pharmaceutical companies developing pediatric and oral-liquid portfolios, this combination can be incorporated into a structured PCD Pharma Franchise range with suitable manufacturing and quality-control systems.
The formulation contains ofloxacin, metronidazole, and simethicone, each having different physical characteristics that need to be considered during product development. The formulation therefore requires more than simple mixing of the ingredients into an aqueous vehicle.
The final suspension may contain suitable suspending agents, wetting materials, viscosity modifiers, sweeteners, flavours, preservatives where applicable, and other approved excipients. Their selection depends on the finalized composition and the desired physical properties of the finished product.
Ofloxacin and metronidazole may require controlled dispersion within the vehicle, while simethicone has different physical behaviour because of its low water solubility and tendency to form a dispersed phase. The manufacturing process should therefore be designed to maintain a consistent distribution of all components.
Uniform wetting of suspended pharmaceutical particles is an important part of manufacturing this type of oral liquid. Poor wetting can lead to floating material, clumping, uneven distribution, or slow redispersion after storage.
The active ingredients can be processed using an appropriate sequence designed around their individual particle characteristics. Controlled premixing and gradual incorporation into the vehicle may help improve dispersion.
Mixing speed and processing duration should be established during formulation development. Excessive agitation can introduce unnecessary air, while insufficient mixing may result in non-uniform distribution. The finished bulk should therefore be evaluated for homogeneity before filling.
The rheological profile of the suspension influences sedimentation, pouring behaviour, filling accuracy, and redispersibility. The viscosity needs to be sufficient to support the intended physical stability without making the product unnecessarily difficult to dispense.
Simethicone presents an additional formulation consideration because it is incorporated as a dispersed component rather than behaving like a conventional water-soluble ingredient. Appropriate emulsification or dispersion technology may be required depending on the selected formulation system.
Physical evaluation can include appearance, colour, odour, pH, viscosity, homogeneity, sedimentation characteristics, and redispersibility. These parameters help establish whether the liquid remains consistent during manufacturing and storage.
Flavour development is an important part of an oral suspension containing multiple active ingredients because the raw materials can contribute distinctive taste and odour characteristics. The flavour and sweetening system should be selected for compatibility with the complete formulation.
During manufacturing, the liquid vehicle is prepared under controlled conditions before the active components and supporting excipients are incorporated according to the approved sequence. Temperature, mixing time, order of addition, and bulk holding conditions can influence the finished product.
In-process sampling can be performed at different stages to confirm that the bulk remains adequately homogeneous. Fill-volume checks and visual inspection can also be incorporated into the manufacturing process.
Finished-product quality testing may include identification and assay of the specified active components, pH, viscosity, appearance, microbial quality, fill volume, redispersibility, and other applicable parameters.
Because this is a multi-component suspension, analytical methods should be appropriately selected to evaluate the individual components without interference from the other ingredients. Suitable validation or qualification supports reliable routine testing.
Stability studies can monitor changes in assay, appearance, colour, pH, viscosity, sedimentation, redispersibility, microbial quality, and other relevant characteristics. The stability program helps establish whether the suspension maintains its intended physical and chemical properties throughout the proposed shelf life.
Packaging for Ofloxacin 50MG, Metronidazole 120 MG with Simethicone 10 MG Suspension should support product stability and convenient dispensing. Suitable pharmaceutical-grade bottles and closures can be evaluated for compatibility with the formulation, leakage resistance, closure integrity, and dispensing performance.
Bottle design, headspace, closure type, and material selection can influence product handling and stability. The packaging system should be supported by compatibility and stability data rather than selected only on the basis of appearance.
For pharmaceutical companies expanding their PCD Pharma Franchise portfolio, this three-component suspension can be included within a structured oral-liquid range supported by defined raw-material specifications, controlled manufacturing procedures, analytical testing, and stability monitoring.
From vehicle preparation and particle wetting to simethicone dispersion, rheological adjustment, flavour development, bulk testing, filling, and packaging, each stage contributes to the consistency of the finished suspension. A formulation-specific manufacturing approach helps maintain uniform distribution, suitable physical characteristics, and product stability throughout the intended shelf life.
Ofloxacin 50MG, Metronidazole 120MG with Simethicone 10MG Suspension formulation, manufacturing, quality control and stability details.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech